Showing 1–24 of 33 results

GlaxoSmithKline (GSK)

GlaxoSmithKline (GSK)

Pharmaceuticals
Our Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology. We are strengthening our R&D pipeline through a focus on immunology, human genetics and advanced technologies to help us deliver transformational new medicines for patients.

The business generated sales of £17 billion in 2020.

GlaxoSmithKline (GSK)

Our marketplace
The global pharmaceuticals market is vast. The US remains a priority market for growth with other key growth areas including emerging markets and Asia Pacific regions.

This trend of increasing demand is expected to continue as the world’s population grows, economies in the emerging markets become more prosperous and global changes in lifestyles affect long-term health.

Janet Liberty, a COPD patient in a Philadelphia garden. Pharmaceuticals. Janet Liberty, a COPD patient
Our strategy
Our strategy is to research and produce innovative, high-quality and needed medicines; making these as accessible as possible to countries at all levels of income and development.

To do this we focus on creating a strong differentiated pipeline, leading in HIV and respiratory, and developing our presence in speciality therapy areas, including oncology and immuno-inflammation.

Our Pharmaceuticals portfolio
Our portfolio is made up of innovative and established medicines and we have leading global positions in respiratory disease and HIV.

We have been a leader in respiratory disease for over 40 years and have a portfolio of mature products. In recent years, we have strengthened and broadened our respiratory portfolio with the addition of new medicines including an inhaled corticosteroid (ICS) and long-acting beta2 agonist (LABA) combination, a long-acting muscarinic antagonist (LAMA) and LABA dual bronchodilator.

Our HIV business is managed through ViiV Healthcare, a global specialist company in HIV that we majority own, with Pfizer and Shionogi as shareholders. ViiV Healthcare is now a leading global company in HIV and has had significant recent success with regulatory approval and industry leading launches of new medicines. ViiV Healthcare has a number of other antiretroviral medicines in clinical development.

r the treatment of conditions such as lupus, urology and anti-infectives.

We also have an Established Products Portfolio (EPP) which includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of our Emerging Markets business where the GSK brand is an important differentiator.

We are exploring different approaches to promote – and speed up – innovation in our labs. Having broken down the traditional, R&D model, our scientists now work in smaller units focused on specific areas of research. This encourages greater entrepreneurialism and accountability. These groups are tasked with seeking out the biological targets involved in disease and creating molecules or biopharmaceuticals that will ultimately become new medicines.